Diagnostic Tests/Kits Products & Reviews

Rapid nucleic acid detection post isothermal amplification for decentralised, point of care molecular testing

Provides sensitive and specific measurements of antibodies against four SARS-CoV-2 proteins: nucleocapsid, receptor binding domain, spike 1, and spike 2 viral proteins.

Provides sensitive and specific quantitation of antibodies against four SARS-CoV-2 proteins: nucleocapsid, receptor binding domain, spike 1, and spike 2 viral proteins.  

Euroimmun offers ChLIA and ELISA tests for fast and efficient measurement of faecal calprotectin in stool samples. The analysis supports the diagnostic differentiation between chronic inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS) in line with current international guidelines. The assays are fully automatable, with random-access processing available for the ChLIA.

BioReady Gold Nanospheres - Bare (Citrate) - 40 nm, 20 OD in aqueous 0.02 mM sodium citrate

BioReady Gold Nanospheres - Bare (Citrate) - 80 nm, 20 OD in aqueous 0.02 mM sodium citrate

BioReady Gold Nanospheres - Streptavidin - 40 nm, 10 OD in aqueous conjugation buffer

BioReady Gold Nanoshells - Streptavidin - 150 nm, 10 OD in aqueous conjugation buffer

In children, luteinizing hormone, along with follicle-stimulating hormone, is used to diagnose delayed and precocious (early) puberty. This assay is sensitive to 0.009 mIU/mL and is more appropriate for use in children. This assay offers a 10-fold increase in analytical sensitivity over existing automated immunoassays.  

In children, follicle-stimulating hormone along with luteinizing hormone, is used to diagnose delayed and precocious (early) puberty. This assay is sensitive to 0.02 IU/L and is more appropriate for use in children. This assay offers a 10-fold increase in analytical sensitivity over existing automated immunoassays.  

Dried blood spot specimen stability makes it a practical alternative to venous blood. Instead of traveling to a clinic to get blood drawn, a blood spot sample can be taken at a convenient site and mailed to a laboratory. It opens new possibilities in testing, such as comparison of historical to current patient results; simplified blood sampling for patients in remote locations, for those who are homebound or those that pre…

The LIAISON® SARS-CoV-2 TrimericS IgG assay enables the reliable detection of Trimeric S spike protein IgG antibodies – the body’s natural defense response against SARS-CoV-2.

Animal-free passive blocking antibody

Animal-free active blocking antibody

The LumiraDx CRP Test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify CRP levels in whole blood and plasma. Used with the LumiraDx Platform, the Test delivers rapid, quantitative results in 4 minutes at the point of care.

The LumiraDx D-Dimer Test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify D-Dimer levels in whole blood and plasma. It is the only direct fingerstick D-Dimer assay available today*, aiding healthcare professionals to exclude deep vein thrombosis (DVT) and pulmonary embolism (PE) in symptomatic patients with confidence** - in only 6 minutes.

The LumiraDx HbA1c test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify HbA1c in fingerstick and venous whole blood. Used with the LumiraDx Platform, the LumiraDx HbA1c test delivers rapid, reliable results in approximately < 7 minutes at the point of care.

The LumiraDx NT-proBNP test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify NT-proBNP in human capillary and venous whole blood and plasma samples (Lithium Heparin). Used with the LumiraDx Platform, the LumiraDx NT-proBNP test delivers rapid, reliable results in 12 minutes at the point of care.

The LumiraDx SARS-CoV-2 Ab Test is a microfluidic immunofluorescence assay for qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform the Test delivers rapid results at the point of care.

The LumiraDx SARS-CoV-2 Ag Test is a microfluidic immunofluorescence assay for the direct and qualitative detection of nucleocapsid protein antigen in nasal and nasopharyngeal swab specimens from individuals suspected of COVID-19 or asymptomatic individuals. Used with the LumiraDx Platform the test delivers rapid results at the point of care.

Lab-comparable results in just 5 minutes - With excellent performance and results in just 5 minutes, the LumiraDx SARS-CoV-2 Ag Ultra test enables you to accurately and confidently test more patients, optimize clinic workflows and help triage patients without delay

The LumiraDx SARS-CoV-2 Ag Pool Test is a rapid microfluidic immunofluorescence assay for the qualitative detection of the nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens pooled from up to 5 individuals suspected of COVID-19 or up to 5 asymptomatic individuals. Used with the LumiraDx Platform the test offers a rapid, scalable and cost-effective screening solution for infectious individuals.

Enzyme Immunoassay for the quantitative determination of Anti-Infliximab antibodies in human serum and plasma.

Is it COVID-19? Is it Flu? Lab-comparable results in minutes. Verify potential infection quickly with a rapid microfluidic assay that provides actionable and lab-comparable results in 12 mins for patients suspected of Flu and/or COVID-19, to help decision making and guide treatment.

Is it RSV? Is it COVID-19? Actionable results in minutes. Verify potential infection and help guide infection control measures quickly with a rapid microfluidic assay that provides actionable results in 12 minutes, for patients suspected of RSV and/or COVID-19.